Idsk -- GAITHERSBURG, Md. (EGMN) – Intravenous phenytoin should continue to be marketed but with revisions to its label that include more information about the risk of “purple glove syndrome” associated with its use, advisors to the Food and Drug Administration recommended on Nov. 3.
